Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran; Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Diabetes Metab Syndr. 2024 Aug;18(8):103110. doi: 10.1016/j.dsx.2024.103110. Epub 2024 Aug 23.
We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.
A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.
A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: -0.211; 95 % CI: -0.257, -0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: -0.087; 95 % confidence interval: -0.120, -0.053; P < 0.001; effect size: -0.166; 95 % confidence interval: -0.200, -0.132; P < 0.001; effect size: -0.230; 95 % confidence interval: -0.288, -0.172; P < 0.001, respectively).
Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.
本研究旨在探讨益生菌、益生元和合生元对糖尿病患者血糖指数的影响。
我们对 PubMed、Scopus 和 Web of Science 进行了全面检索，检索时间从建库至 2023 年 4 月。采用随机效应模型进行研究分析。此外，还进行了敏感性和亚组分析，以探究潜在的异质性来源。采用 AMSTAR2 清单评估研究质量。采用 Comprehensive Meta-Analysis version 3 进行研究分析。
共有 31 项研究纳入最终分析。荟萃分析结果显示，肠道微生物治疗可显著降低 2 型糖尿病患者的血清空腹血糖水平（效应量：-0.211；95%置信区间：-0.257，-0.164；P<0.001）。此外，肠道微生物治疗与改善血清空腹胰岛素、糖化血红蛋白和稳态模型评估的胰岛素抵抗（效应量：-0.087；95%置信区间：-0.120，-0.053；P<0.001；效应量：-0.166；95%置信区间：-0.200，-0.132；P<0.001；效应量：-0.230；95%置信区间：-0.288，-0.172；P<0.001）水平也存在显著相关性。
本研究结果表明，肠道微生物群调节对 2 型糖尿病患者的血糖谱具有良好的作用。可以考虑将这些药物作为辅助治疗方法。
